Publications by authors named "Marco Aurelio Cigognini"
Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial.
Marco Aurélio Cigognini Alia Garrudo Guirado Denise van de Meene Mônica Andréia Schneider Mônica Sarah Salomon
Front Psychiatry
July 2022
Article Synopsis
- Ketamine is being studied for its effectiveness and safety in treating treatment-resistant depression (TRD) compared to established medications like escitalopram and aripiprazole, with a focus on both short-term and long-term outcomes.
- The trial involves a randomization of participants aged 18-40 to receive either intramuscular ketamine or the control medication over a period of 28 weeks, assessing changes in depression severity and monitoring vital signs and neuropsychological effects.
- Results could provide insights into using ketamine as a rapid, low-cost treatment option for TRD, potentially leading to better patient outcomes and resource management.
Objective: To determine the point prevalence of depressive disorders in medical inpatients, to identify related sociodemographic and medical factors and to evaluate the psychotropic treatment given.
Method: A cross-sectional study identifying the prevalence of depressive disorders and related factors combined with a prospective longitudinal study evaluating the psychopharmacological treatment were conducted. Medical inpatients, aged 18 years or older, presenting suitability to be interviewed and giving written informed consent were selected.